Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic SyndromesMaria Teresa Voso, Giuseppe Leone, Valeria Santini et al.|Clinical Cancer Research|2009Cited by 101
Differences among young adults, adults and elderly chronic myeloid leukemia patientsFabio Castagnetti, Mariella Girasoli, Gabriele Gugliotta et al.|Annals of Oncology|2014Cited by 99
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Alessandro Nobili et al.|Oncotarget|2016Cited by 35
Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletionEsther N. Oliva, Roberto Latagliata, Maria Cuzzola et al.|European Journal Of Haematology|2010Cited by 29
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studyEsther Natalie Olíva, Roberto Latagliata, Maria Cuzzola et al.|Annals of Hematology|2012Cited by 27